N-(6,7-dimethoxyquinazolin-4-yl)-N-phenyl-N-ethylamine hydrochloride

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-(6,7-dimethoxyquinazolin-4-yl)-N-phenyl-N-ethylamine hydrochloride
• 英文别名: N-ethyl-6,7-dimethoxy-N-phenylquinazolin-4-amine;hydrochloride
• 化学式: C₁₈H₁₉N₃O₂*ClH
• 分子量: 345.829
• InChiKey: ADNCIQVAAFFSDO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.23
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  47.5
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  N-乙基苯胺 、 4-氯-6,7-二甲氧基喹唑啉 在 盐酸 作用下， 生成 N-(6,7-dimethoxyquinazolin-4-yl)-N-phenyl-N-ethylamine hydrochloride
  参考文献：
  名称：

  The synthesis and SAR of new 4-(N-alkyl-N-phenyl)amino-6,7-dimethoxyquinazolines and 4-(N-alkyl-N-phenyl)aminopyrazolo[3,4-d]pyrimidines, inhibitors of CSF-1R tyrosine kinase activity

  摘要：

  We have identified moderately potent and selective inhibitors of CSF-IR tyrosine kinase activity.(1) A preliminary SAR study resulted in the identification of compounds 11 and 20 as the most potent analogues in the series (IC50 = 0.18 mu M). The 3D-conformation of the 4-(N-alkyl-N-phenyl)-aminoquinazolines has been proposed to be important to the overall selectivity and activity. (C) 1997, Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(97)00035-8

文献信息

• Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
  申请人：——

  公开号：US20040014774A1

  公开（公告）日：2004-01-22

  This invention relates to the modulation and/or inhibition of cell signaling, cell proliferation, cell inflammatory response, the control of abnormal cell growth and cell reproduction. More specifically, this invention relates to the use of mono- and/or bicyclic aryl or heteroaryl quinazoline compounds in inhibiting cell proliferation, including compounds which are useful protein tyrosine kinase (PTK) inhibitors. The method of treating cell proliferation and/or differentiation or mediator release using said quinazoline compounds and their use in pharmaceutical compositions is described.

  本发明涉及细胞信号传导、细胞增殖、细胞炎症反应、控制异常细胞生长和细胞繁殖的调节和/或抑制。更具体地，本发明涉及使用单环和/或双环芳基或杂芳基喹唑啉化合物抑制细胞增殖，包括对蛋白酪氨酸激酶（PTK）的抑制剂有用的化合物。描述了使用所述喹唑啉化合物治疗细胞增殖和/或分化或介质释放的方法以及它们在制药组合物中的应用。
• Quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
  申请人：Aventis Pharmaceuticals Products Inc.

  公开号：EP1488792A2

  公开（公告）日：2004-12-22

  This invention relates to the modulation and/or inhibition of cell signaling, cell proliferation, cell inflammatory response, the control of abnormal cell growth and cell reproduction. More specifically, this invention relates to the use of quinazoline compounds in inhibiting cell proliferation, including compounds which are useful protein tyrosine kinase (PTK) inhibitors. The method of treating cell proliferation and/or differentiation or mediator release using said quinazoline compounds and their use in pharmaceutical compositions is described.

  本发明涉及细胞信号、细胞增殖、细胞炎症反应、异常细胞生长控制和细胞繁殖的调节和/或抑制。更具体地说，本发明涉及喹唑啉化合物在抑制细胞增殖方面的用途，包括作为有用的蛋白酪氨酸激酶（PTK）抑制剂的化合物。本发明描述了使用所述喹唑啉化合物治疗细胞增殖和/或分化或介质释放的方法及其在药物组合物中的用途。
• PROTEIN TYROSINE KINASE ARYL AND HETEROARYL QUINAZOLINE COMPOUNDS HAVING SELECTIVE INHIBITION OF HER-2 AUTOPHOSPHORYLATION PROPERTIES
  申请人：RHONE-POULENC RORER PHARMACEUTICALS, INC.

  公开号：EP0831831A1

  公开（公告）日：1998-04-01
• EP0831831A4
  申请人：——

  公开号：EP0831831A4

  公开（公告）日：1998-05-27
• ARYL AND HETEROARYL QUINAZOLINE COMPOUNDS WHICH INHIBIT CSF-1R RECEPTOR TYROSINE KINASE
  申请人：RHONE-POULENC RORER PHARMACEUTICALS INC.

  公开号：EP0871448A1

  公开（公告）日：1998-10-21